We believe that, even as radiation therapy vendors work to improve clinical efficiency, the highest-quality patient treatments must remain our industry's primary focus
MADISON, Wis. (PRWEB) March 26, 2008
"We believe that, even as radiation therapy vendors work to improve clinical efficiency, the highest-quality patient treatments must remain our industry's primary focus," said Fred Robertson, CEO of TomoTherapy. "With this challenge, we aim to provide a forum for U.S. clinicians to objectively review the quality that a continuous helical TomoTherapy treatment affords over a two-minute, single-rotation RapidArc(TM) delivery."
Cancer centers are encouraged to learn more about this challenge, and to register, at TomoTherapy.com.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
(C)2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated. RapidArc is a trademark of Varian Medical Systems.